Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

product recall

- PMLiVE

Teva faces US marketing investigation

Department of Justice to probe promotion tactics for Copaxone and Azilect

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

- PMLiVE

Teva names Vigodman CEO and makes bid for NuPathe

Israeli pharma company confirms Jeremy Levin’s replacement

- PMLiVE

Key Teva shareholder backs Vigodman as next CEO

Board director tipped to replace Jeremy Levin at Israeli pharma firm

- PMLiVE

FDA to assess safety of Boehringer’s Pradaxa

US regulator plans study to compare the anticoagulant with warfarin

China flag thumb

China says hepatitis B vaccines not cause of infant deaths

But suspension on production remains in place

- PMLiVE

Teva’s vice chair steps down

Amir Elstein to take over from Moshe Many

- PMLiVE

Teva expects big things from improved drug programme

Aims to market enhanced versions of existing medicines

- PMLiVE

FDA lifts restrictions on Avandia use

US regulator says GSK’s diabetes drug does not increase heart attack risk

- PMLiVE

Ariad’s cancer drug to remain on EU market

But EMA restricts use of Iclusig due to blood clot risk

- PMLiVE

Teva withdraws US filing for cancer biologic

FDA requests more data for balugrastim

- PMLiVE

EMA warns of excessive caution by regulators

Agency says risk aversion could deny patients new treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links